Spondyloarthritis & psoriatic arthritis
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study
Authors' conclusion
Vunakizumab demonstrated superior efficacy to placebo and was well tolerated with an acceptable safety profile in patients with active PsA.
Study context
- Population
- Patients aged 18–75 years with a confirmed diagnosis of active PsA
- Participants
- 38 / 37 / 37
- Comparison
- SC vunakizumab 120 mg or 240 mg vs placebo at weeks 0, 2, 4 and 8
- Vunakizumab 120 mgn = 38
- Vunakizumab 240 mgn = 37
- Placebon = 37reference
- Primary endpoint
- ACR20 response rate
- Follow-up
- Week 12
Methodological detailsphase 2, multicentre, double-blind, placebo-controlled
- Phase 2
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Vunakizumab 120 mg vs Placebo: P = 0.02 · Vunakizumab 240 mg vs Placebo: P = 0.001
Further findings
Sustained improvement, incl. patients switched from placebo after week 12 · 24 weeks
- Improvements were sustained through 24 weeks and were noted in patients who switched from placebo after week 12
Safety
TEAEs · 12-week core treatment period · analogous frequencies
Severe treatment-emergent adverse events (TEAEs) · 12-week core treatment period
- No severe TEAEs occurred
Original publication
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study. Rheumatology (Oxford). Published 3 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →